Delivery Order SPE2DB20D1051-SPE2DB25FD9MN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,265.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 15, 2025. The contract represents a firm fixed price, non-set-aside delivery order executed on September 12, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award is a child contract under AmerisourceBergen's substantial $999,999,999...
- The Defense Logistics Agency awarded a $2,661.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract represents a competitive, non-set-aside award under a firm fixed-price arrangement with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $11.3K delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on September 17, 2025, with completion targeted for September 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical. The pharmaceutical supply will be delivered to the company's location in...
- The Defense Logistics Agency awarded a $5,863.86 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,853.05 on August 7, 2025, for the supply of Novolog 100 Unit/mL Flexpen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. As a child order under a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,380.61 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of June 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $12,030.04 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 4, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $8,434.80. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 24, 2025. This delivery order is...
- The Defense Logistics Agency awarded a $1,518.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a non-set-aside competitive award with an ultimate completion date of May 19, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a $1,082.55 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of June 2, 2025. This firm fixed price contract, issued on May 30, 2025, represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion...
- SPE2DB20D1051Indefinite Delivery Contract
- SPE2DB20D1051-SPE2DB25FD9MNDelivery Order
The Defense Logistics Agency awarded a $1,150.32 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on September 16, 2025, with completion expected by September 17, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999 pharmaceutical supply agreement running through December 2026 that enables the company to furnish pharmaceuticals and medical supplies globally to military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Department of Defense and related healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply diverse pharmaceutical products ranging from specialty medications to vaccines and medical devices across multiple therapeutic areas. This delivery order for insulin pens reflects the company's ongoing role in supplying essential diabetes management medications and other critical pharmaceuticals to support military personnel and veterans through DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/16/25 |